Integra Therapeutics develops gene writing tools that combine CRISPR-Cas precision with engineered piggybac transposase for efficient delivery of both small and large DNA payloads. The technology addresses limitations in gene therapy related to gene size, precision, and stability, aiming to cure genetic and oncological diseases with high unmet medical needs.
Funding
$6.8M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
EAFounders
Product
Problem
Current gene therapies face limitations in delivering large genetic payloads, achieving precise gene editing, and ensuring long-term therapeutic stability, hindering their effectiveness in treating genetic and oncological diseases. These challenges restrict the scope of treatable conditions and necessitate improved gene writing tools.
Solution
Integra Therapeutics is developing advanced gene writing tools that combine the precision of CRISPR-Cas technology with an engineered piggybac transposase. This platform, called FiCAT, enables efficient delivery of both small and large DNA payloads, overcoming size constraints in gene therapy. By integrating CRISPR-Cas for targeted editing and piggybac transposase for efficient gene transfer, Integra aims to enhance the scope, efficiency, and safety of advanced therapies. The technology seeks to provide more precise and stable gene modifications, ultimately improving the treatment of genetic and oncological diseases with high unmet medical needs.
Target Audience
The primary target audience includes researchers and clinicians in the fields of gene therapy, oncology, and genetic diseases seeking advanced tools for precise and efficient gene editing and delivery.
Features
- FiCAT platform combines CRISPR-Cas precision with piggybac transposase efficiency.
- Enables delivery of both small and large DNA payloads.
- Aims to improve the scope, efficiency, and safety of advanced therapies.
- Designed for precise and stable gene modifications.